Biktarvy Gilead Sciences | Bictegravir / Emtricitabine / TAF | INSTI + NRTI/NtRTI | Reimbursed | Fully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI] | 14/09/2026 |
Celsentri ViiV Healthcare | Maraviroc | Entry Inhibitor | Reimbursed | Fully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI] | 14/09/2026 |
Delstrigo Merck | Doravirine / Lamivudine / Tenofovir DF | NNRTI + NRTI/NtRTI | Reimbursed | Fully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI] | 14/09/2026 |
Descovy Gilead Sciences | Emtricitabine / TAF | NRTI | Reimbursed | Fully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI] | 14/09/2026 |
Dovato ViiV Healthcare | Dolutegravir / Lamivudine | INSTI + NRTI | Reimbursed | Fully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI] | 14/09/2026 |
Edurant Janssen | Rilpivirine | NNRTI | Reimbursed | Fully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI] | 14/09/2026 |
Generic TDF/FTC (Emtricitabine/Tenofovir DF) Multiple (Generics) | Emtricitabine / Tenofovir DF | NRTI | Reimbursed | Fully financed through the national health insurance framework. [Source: G-BA / RKI] | 14/09/2026 |
Genvoya Gilead Sciences | Elvitegravir / Cobicistat / Emtricitabine / TAF | INSTI + NRTI/NtRTI + pharmacokinetic enhancer | Reimbursed | Fully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI] | 14/09/2026 |
Intelence Janssen | Etravirine | NNRTI | Reimbursed | Fully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI] | 14/09/2026 |
Isentress Merck | Raltegravir | INSTI | Reimbursed | Fully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI] | 14/09/2026 |
Juluca ViiV Healthcare | Dolutegravir / Rilpivirine | INSTI + NNRTI | Reimbursed | Fully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI] | 14/09/2026 |
Kaletra AbbVie | Lopinavir / Ritonavir | PI | Reimbursed | Fully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI] | 14/09/2026 |
Odefsey Gilead Sciences | Rilpivirine / Emtricitabine / TAF | NNRTI + NRTI/NtRTI | Reimbursed | Fully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI] | 14/09/2026 |
Pifeltro Merck | Doravirine | NNRTI | Reimbursed | Fully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI] | 14/09/2026 |
Prezista Janssen | Darunavir | PI | Reimbursed | Fully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI] | 14/09/2026 |
Rekambys Janssen | Rilpivirine | Long-Acting NNRTI | Reimbursed | Long-acting injectable rilpivirine used with cabotegravir for maintenance treatment in eligible virologically suppressed patients. The existing Germany record for the complete Vocabria / Rekambys regimen is classified as 'Available and Reimbursed', so this required rilpivirine component uses the same access and reimbursement status. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys; https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121] | 14/09/2026 |
Rukobia ViiV Healthcare | Fostemsavir | Attachment Inhibitor | Reimbursed | Fully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI] | 14/09/2026 |
Sunlenca Gilead Sciences | Lenacapavir | Capsid Inhibitor | Reimbursed | Fully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI] | 14/09/2026 |
Symtuza Janssen | Darunavir / Cobicistat / Emtricitabine / TAF | PI + NRTI/NtRTI + pharmacokinetic enhancer | Reimbursed | Fully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. EU regulatory update (as of 5 Oct 2026): on 25 June 2026 the CHMP adopted a positive opinion extending the indication, with a new 675/150/200/10 mg tablet strength, to adults and paediatric patients aged 6 years and older weighing at least 25 kg (previously adolescents aged 12 years and older weighing at least 40 kg). European Commission decision not confirmed during this review; national availability and reimbursement of the new strength not verified. [Sources: G-BA / RKI; https://www.ema.europa.eu/en/medicines/human/variation/symtuza] | 14/09/2026 |
Tivicay ViiV Healthcare | Dolutegravir | INSTI | Reimbursed | Fully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI] | 14/09/2026 |
Triumeq ViiV Healthcare | Dolutegravir / Abacavir / Lamivudine | INSTI + NRTI | Reimbursed | Fully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI] | 14/09/2026 |
Truvada Gilead Sciences | Emtricitabine / Tenofovir DF | NRTI | Reimbursed | Fully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI] | 14/09/2026 |
Vocabria ViiV Healthcare | Cabotegravir | INSTI | Reimbursed | Fully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Sources: G-BA / RKI; https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121] | 14/09/2026 |
Vocabria / Rekambys ViiV Healthcare / Janssen | Cabotegravir / Rilpivirine | Long-Acting ART | Reimbursed | EMA approved. Fully or partially reimbursed under the national health system for virologically suppressed patients. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Sources: G-BA / RKI; https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121] | 14/09/2026 |
Generic TLD (Tenofovir/Lamivudine/Dolutegravir) Multiple (Generics) | Tenofovir DF / Lamivudine / Dolutegravir | INSTI + NRTI/NtRTI | Not available | Generic combinations are typically not procured as branded single-tablet regimens are widely available. [Source: G-BA / RKI] | 14/09/2026 |
Generic TLE (Tenofovir/Lamivudine/Efavirenz) Multiple (Generics) | Tenofovir DF / Lamivudine / Efavirenz | NNRTI + NRTI/NtRTI | Not available | Generic combinations are typically not procured as branded single-tablet regimens are widely available. [Source: G-BA / RKI] | 14/09/2026 |
Apretude ViiV Healthcare | Cabotegravir (PrEP) | INSTI (Long-Acting PrEP) | Under review | Long-acting injectable cabotegravir with oral lead-in tablets, for pre-exposure prophylaxis in adults and adolescents from 12 years weighing at least 35 kg. EMA confirms an EU/EEA-wide marketing authorisation granted by the European Commission on 19 September 2023. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/apretude] | 14/09/2026 |
Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris Viatris Limited | Emtricitabine / Rilpivirine / Tenofovir alafenamide | NNRTI + NRTI/NtRTI | Under review | EMA confirms an EU/EEA-wide marketing authorisation issued on 19 August 2025. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris] | 14/09/2026 |
Emtricitabine / Tenofovir alafenamide Viatris Viatris Limited | Emtricitabine / Tenofovir alafenamide | NRTI/NtRTI | Under review | EMA confirms an EU/EEA-wide marketing authorisation issued on 18 July 2025. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-tenofovir-alafenamide-viatris] | 14/09/2026 |
Emtriva Gilead Sciences | Emtricitabine | NRTI | Under review | Emtricitabine is a nucleoside reverse transcriptase inhibitor used with other antiretroviral medicines for HIV-1 treatment. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtriva] | 14/09/2026 |
Epivir ViiV Healthcare | Lamivudine | NRTI | Under review | Lamivudine is a nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/epivir] | 14/09/2026 |
Eviplera Gilead Sciences | Rilpivirine / Emtricitabine / Tenofovir DF | NNRTI + NRTI/NtRTI | Under review | A once-daily fixed-dose HIV-1 regimen containing rilpivirine, emtricitabine and tenofovir disoproxil; resistance history and viral-load restrictions apply. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/eviplera] | 14/09/2026 |
Evotaz Bristol Myers Squibb | Atazanavir / Cobicistat | PI + pharmacokinetic enhancer | Under review | EMA confirms an EU/EEA-wide marketing authorisation issued on 13 July 2015. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/evotaz] | 14/09/2026 |
Kivexa ViiV Healthcare | Abacavir / Lamivudine | NRTI | Under review | A fixed-dose NRTI backbone containing abacavir and lamivudine; HLA-B*5701 screening is required before abacavir treatment. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/kivexa] | 14/09/2026 |
Norvir AbbVie | Ritonavir | PI + pharmacokinetic enhancer | Under review | Ritonavir is a protease inhibitor used mainly at low dose as a pharmacokinetic enhancer for other protease inhibitors. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. EU regulatory update (as of 5 Oct 2026): on 18 September 2025 the CHMP adopted a positive opinion recommending changes to the existing indication and contraindications of Norvir, including guidance that when ritonavir is used as a pharmacokinetic enhancer the SmPC of the co-administered protease inhibitor should be consulted for contraindications. European Commission decision not confirmed during this review. [Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/norvir; https://www.ema.europa.eu/en/medicines/human/variation/norvir] | 14/09/2026 |
Retrovir ViiV Healthcare | Zidovudine | NRTI | Under review | Zidovudine is a nucleoside reverse transcriptase inhibitor used with other antiretroviral medicines; it is now generally a specialised or alternative treatment option. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/retrovir] | 14/09/2026 |
Reyataz Bristol Myers Squibb | Atazanavir | PI | Under review | EMA confirms an EU/EEA-wide marketing authorisation issued on 2 March 2004. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/reyataz] | 14/09/2026 |
Rezolsta Janssen | Darunavir / Cobicistat | PI + pharmacokinetic enhancer | Under review | A fixed-dose combination of darunavir and cobicistat used with other antiretrovirals. EMA's CHMP issued a positive opinion on 25 June 2026 for a dispersible formulation and paediatric use from age 3 years and 15 kg. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta] | 14/09/2026 |
Stribild Gilead Sciences | Elvitegravir / Cobicistat / Emtricitabine / Tenofovir DF | INSTI + NRTI/NtRTI + pharmacokinetic enhancer | Under review | A once-daily fixed-dose HIV-1 regimen containing an integrase inhibitor, pharmacokinetic enhancer and two reverse transcriptase inhibitors. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/stribild] | 14/09/2026 |
Viread Gilead Sciences | Tenofovir DF | NtRTI | Under review | Tenofovir disoproxil is a nucleotide reverse transcriptase inhibitor used with other antiretrovirals for HIV-1 treatment; renal and bone monitoring may be relevant. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/viread] | 14/09/2026 |
Yeytuo Gilead Sciences | Lenacapavir (PrEP) | Capsid Inhibitor (Long-Acting PrEP) | Under review | Twice-yearly injectable lenacapavir for pre-exposure prophylaxis; a separate marketing authorisation from Sunlenca, which covers treatment. The European Commission granted an EU/EEA-wide marketing authorisation on 26 August 2025 following accelerated EMA assessment. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/yeytuo] | 14/09/2026 |
Ziagen ViiV Healthcare | Abacavir | NRTI | Under review | Abacavir is a nucleoside reverse transcriptase inhibitor used in combination therapy; HLA-B*5701 screening is required before treatment. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/ziagen] | 14/09/2026 |